INS and type 2 diabetes mellitus: The first observation of note is that isCGM users with type 2 diabetes on insulin therapy achieve comparable and sustained reductions in HbA1c after initiating isCGM, irrespective of treatment with either intensive multiple daily injections or basal insulin-only regimens.